Replies to post #175362 on Biotech Values

[DewDiligence]

OGXI/TEVA—Custirsen fails phase-3 trial in mCRPC:

http://www.sec.gov/Archives/edgar/data/818686/000130901414000280/exhibit1.htm

…the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival (OS) in men with metastatic CRPC, compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p-value 0.207).

OGXI was down 60% today.